← FDA DRUG APPROVALS

FDA ANDA · ANDA076757

CIPROFLOXACIN IN DEXTROSE 5%

Sponsor: HIKMA FARMACEUTICA

APPLICATION
ANDA076757
TYPE
ANDA
ORIGINAL APPROVAL
2008-04-21
LATEST ACTION
2024-09-20
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CIPROFLOXACIN IN DEXTROSE 5%Discontinued
CIPROFLOXACIN 200MG/100ML · INJECTABLE · INJECTION

Approval history

2024-09-20Labeling · Supplement 10 · standardAP
2019-05-03Labeling · Supplement 9 · standardAP
2019-04-18Labeling · Supplement 8 · standardAP
2018-10-18Labeling · Supplement 7 · standardAP
2018-10-15Labeling · Supplement 5 · standardAP
2018-10-15Labeling · Supplement 6 · standardAP
2014-06-25Labeling · Supplement 3 · standardAP
2011-06-23Labeling · Supplement 2AP
2009-07-09Labeling · Supplement 1AP
2008-04-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →